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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.032Nogo-B (reticulon 4B) accentuates hepatic ﬁbrosis and cirrhosis, but the mechanism remains unclear.
The aim of this study was to identify the role of Nogo-B in hepatic stellate cell (HSC) apoptosis in
cirrhotic livers. Cirrhosis was generated by carbon tetrachloride inhalation in wild-type (WT) and Nogo-
A/B knockout (Nogo-B KO) mice. HSCs were isolated from WT and Nogo-B KO mice and cultured for
activation and transformation to myoﬁbroblasts (MF-HSCs). Human hepatic stellate cells (LX2 cells)
were used to assess apoptotic responses of activated HSCs after silencing or overexpressing Nogo-B.
Livers from cirrhotic Nogo-B KO mice showed signiﬁcantly reduced ﬁbrosis (P < 0.05) compared with WT
mice. Apoptotic cells were more prominent in ﬁbrotic areas of cirrhotic Nogo-B KO livers. Nogo-B KO MF-
HSCs showed signiﬁcantly increased levels of apoptotic markers, cleaved poly (ADP-ribose) polymerase,
and caspase-3 and -8 (P < 0.05) compared with WT MF-HSCs in response to staurosporine. Treatment
with tunicamycin, an endoplasmic reticulum stress inducer, increased cleaved caspase-3 and -8 levels in
Nogo-B KO MF-HSCs compared with WT MF-HSCs (P < 0.01). In LX2 cells, Nogo-B knockdown enhanced
apoptosis in response to staurosporine, whereas Nogo-B overexpression inhibited apoptosis. The
absence of Nogo-B enhances apoptosis of HSCs in experimental cirrhosis. Selective blockade of Nogo-B
in HSCs may represent a potential therapeutic strategy to mitigate liver ﬁbrosis. (Am J Pathol 2013,
182: 786e795; http://dx.doi.org/10.1016/j.ajpath.2012.11.032)Supported by grants R01DK082600 and a Yale Liver Center Pilot
Project Award (P30-34989) from the NIH (Y.I.), a Female Researcher
Science grant from Shiseido Japan (A.S.), and a VA merit award (C.C.).Liver ﬁbrosis and its end-stage manifestation of cirrhosis
represent clinical challenges worldwide. Hepatic stellate cell
(HSC) activation is the cardinal feature that results in hepatic
ﬁbrosis. When stimulated by reactive oxygen species or
cytokines in response to various hepatic insults, quiescent
HSCs are transformed to myoﬁbroblasts (MF-HSCs) that
proliferate and secrete collagen.1e4 Studies have shown that
apoptosis of activated HSCs can reverse ﬁbrosis.5e13 Thus,
the mechanisms that control MF-HSC apoptosis may repre-
sent potential therapeutic targets that result in reduced
ﬁbrosis.14e16
Nogo-B, also known as reticulon 4B, is a member of the
reticulon protein family that is localized primarily to the
endoplasmic reticulum (ER).17,18 Four groups of reticulons
(1, 2, 3, and 4) exist, and each has multiple isoforms. Retic-
ulon 4 has three isoforms, Nogo-A, B, and C. The most
recognized isoform, Nogo-A (200 kDa), a potent neuralstigative Pathology.
.outgrowth inhibitor,19e21 is expressed mainly in the nervous
system.22e24 Nogo-C (25 kDa) is highly expressed in the
differentiated muscle ﬁbers and somewhat in the brain,17,18,22
however, its function remains unclear.
Nogo-B (55 kDa), a splice variant of Nogo-A, is expressed in
most tissues and has been reported for its role in modulating
endothelial and smooth muscle cellular responses after injury
in a variety of organs/tissues, including blood vessels,25,26
lung,27,28 kidney,29 and liver.30 We previously showed that
the absence of Nogo-B in a murine model blocks the progres-
sion of ﬁbrosis/cirrhosis and the development of portal hyper-
tension.30 Further, we showed that lack of Nogo-B decreases
the levels of a-smooth muscle actin (a-SMA), a marker of
Nogo-B, Hepatic Apoptosis, and FibrosisMF-HSCs, in murine cholestatic livers. These ﬁndings led us to
hypothesize that absence of Nogo-B may increase the suscep-
tibility of MF-HSCs to apoptosis, thereby reducing ﬁbrosis/
cirrhosis in mice. In this study, we investigated the role of
Nogo-B in MF-HSC apoptosis in vivo and in vitro.
Materials and Methods
Animals
All animal studies were approved by the Institutional Animal
Care and Use Committees of Yale University and the Veterans
Affairs Connecticut Health Care System. Studies were per-
formed in adherence with the NIH Guide for the Care and Use
of Laboratory Animals. Nogo-A/B knockout (Nogo-B KO)
mice were a gift from Stephen Strittmatter (Yale University,
New Haven, CT)31 and Mark Tessier-Lavigne (The Rock-
efeller University, New York, NY).32
Induction of Hepatic Fibrosis and Cirrhosis
Seven male Nogo-B KO and their littermate wild-type (WT)
mice at the age of 1 month were exposed to carbon tetra-
chloride (CCl4) by inhalation for 12weeks.
33,34 Phenobarbital
(0.35 g/L) was added to the drinkingwater 3 days before CCl4
exposure to accentuate ﬁbrosis/cirrhosis. Mice were placed in
a gas chamber (60  40  20 cm) under a fume hood and
exposed to CCl4 gas three times a week. The duration of CCl4
inhalation was 1 to 2 minutes for the ﬁrst 3 weeks and was
increased to 3 to 5 minutes thereafter. CCl4 exposure was
stopped 5 to 7 days before the experiment. Phenobarbital
was no longer added to the drinking water once CCl4 expo-
sure ended. Age-matched untreated WT and Nogo-B KO
mice were used as treatment controls. Liver samples were
isolated and ﬁxed in formalin or directly embedded in optimal
cutting temperature compound.
Bile duct ligation also was performed in mice as
described.30 Male Nogo-B KO and their littermate WT mice
underwent bile duct ligation surgery at 2 months of age.35
Liver samples from these mice were collected 4 weeks after
surgery and directly embedded inOCT for histologic analyses.
Sirius Red Staining
Histologic specimens were embedded in parafﬁn and cut
into 6-mmethick sections. Sections were deparafﬁnized by
washing in xylene three times for 5 minutes each time, and
rehydrated with 100%, 90%, and 70% ethanol for 5 minutes
each time. After rinsing in distilled water for 5 minutes,
sections were incubated in 0.1% Sirius Red solution (Sigma-
Aldrich, St. Louis, MO) for 90minutes, soaked in 0.5% acetic
acid buffer, and dehydrated gradually with 70%, 90%, and
100% ethanol, and washed three times with xylene for
5 minutes each. Fibrosis was determined by calculating the
percentage of Sirius redepositive area (ie, collagen-positive
area) over the total area analyzed. ImageJ 1.43u softwareThe American Journal of Pathology - ajp.amjpathol.org(Wayne Rasband, NIH, Bethesda, MD) was used for image
analysis of the entire liver sections. At least 20 images per
liver section were taken randomly and used for the analyses.30
Hydroxyproline Assay
Hydroxyproline levels were measured as described.30
Brieﬂy, frozen liver tissues were homogenized in 6 N HCl
and heated at 110C in a heating block for 20 hours. After
cooling, the samples were ﬁltered and neutralized with 2.2%
NaOH in citrate acetate buffer. Chloramine-T solution (0.141
g chloramine-T, 2 mL H2O, 3 mL methoxyethanol, and 5 mL
citrate acetate buffer) was added to neutralized homogenate,
standard hydroxyproline solution, or citrate acetate buffer,
and incubated for 20 minutes at room temperature. Then,
perchloric acid was added to the reaction mixture and incu-
bated for 20 minutes. Finally, dimethyl benzaldehyde solu-
tion (2 g dimethyl benzaldehyde in 10 mL methoxyethanol)
was added and incubated at 60C for 20 minutes. After
cooling, the absorbance was measured at 550 nm by the
Synergy 2 Multi-Mode Microplate reader (BioTek Instru-
ments, Winooski, VT).
Quantitative Real-Time PCR Analysis
Quantitative real-time PCR analysis was performed as
described.30 Brieﬂy, the total RNA from approximately 50mg of
frozen mouse livers was isolated using TRIzol reagent (Sigma-
Aldrich).Onemicrogramof the totalRNAwasusedasa template
to synthesize cDNA using a Transcriptor First Strand cDNA
Synthesis kit (Roche Diagnostics). Then, cDNA was diluted 5
times to be used as a real-timePCR template.Real-timePCRwas
performed using ABI 7500 SDS software version 1.3 (Applied
Biosystems, Foster City, CA). TaqMan gene expression assays
(Applied Biosystems) were used for measuring glyceraldehyde-
3-phosphate dehydrogenase (Mm99999915_g1), collagen type
Ia (Mm00801666_g1), and transforming growth factor-b1
(Mm01178820_m1) gene expression.
Immunohistochemistry
Parafﬁn-embedded sections (6 mm thick) were deparafﬁnized
and rehydrated as described earlier. Antigen retrieval was
performed by placing sections in 10 mmol/L sodium citrate
buffer (pH6.0) then heated in amicrowave, placed in a steamer
for 30 minutes, and steadily cooled down on the bench top for
20 minutes. Sections then were treated with 3% hydrogen
peroxidase diluted with methanol, followed by blocking with
5% donkey serum plus 1% bovine serum albumin in PBS.
After blocking nonspeciﬁc biotin and avidin using a kit
(avidin/biotin blocking kit; Vector Laboratories, Burlingame,
CA), sections were incubated overnight at 4C with cleaved
caspase-3 antibody (rabbit, 1:100; Cell Signaling, Danvers,
MA). After washing three times with Tris-buffered salinewith
0.05% Tween 20 (TBST) for 5 minutes, sections were incu-
bated with biotinylated anti-rabbit IgG (1:500; Jackson787
Tashiro et alImmunoResearch Laboratories, West Grove, PA) and avidin-
conjugated horseradish peroxidase (Vector Laboratories) for
30 minutes each at room temperature. After washing three
times with TBST, sections were incubated with 3,30-dia-
minobenzidine substrate (Vector Laboratories) for color
development, followed by counterstaining with hematoxylin.
Sections then were dehydrated and mounted. Images were
taken using a light microscope (Eclipse 80i; Nikon, Melville,
NY) and analyzed by Image J 1.43u software.
Dual Staining of TUNEL and a-SMA
OCT-embedded frozen liver tissues were cut into 6-mme
thick sections and ﬁxed with 4% paraformaldehyde in PBS for
20 minutes at room temperature, followed by washing with
PBS three times for 5 minutes each. Antigen retrieval was
performed by placing sections in 10 mmol/L sodium citrate
buffer at pH 6.0, then heated in a microwave, placed in
a steamer for 30 minutes, and steadily cooled down on the
bench top for 20 minutes. Sections were incubated with
a blocking buffer including 5% donkey serum plus 1% bovine
serum albumin in PBSe0.3% Triton X-100 for 1 hour, fol-
lowed by treatment with mouse Ig blocking reagent (Vector
Laboratories) for 1 hour at room temperature. Sections then
were incubated with a mouse monoclonal antiea-SMA
(1:1000; Sigma-Aldrich) at room temperature for 1 hour. After
washing three times with TBST for 5 minutes each, sections
were incubated with Alexa Fluor 555 donkey anti-mouse IgG
(1:500; Invitrogen, Grand Island, NY) for 30 minutes at room
temperature. After these processes, TUNEL staining was per-
formed using a commercial kit (In Situ Cell Death Detection
Kit; Roche Diagnostics, Indianapolis, IN) for 1 hour at room
temperature. After washing three times with TBST for 5
minutes each, sections were mounted with DAPI-containing
media (Invitrogen). Images were taken with a ﬂuorescent
microscope (Eclipse E800; Nikon) and recorded using Open-
lab3 software version 5.5.2 (PerkinElmer, Waltham, MA).
Isolation of HSCs
PrimaryHSCswere isolated fromWTandNogo-BKOmice by
in situperfusionof liverswith pronase-collagenase, followedby
density gradient centrifugation using Nycodenz (Histodenz;
Sigma-Aldrich) density gradients as described.36,37 HSCs were
cultured in Dulbecco’s modiﬁed Eagle’s medium with high
glucose (DMEM; Life Technologies, Grand Island, NY) sup-
plemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin, 100 mg/mL streptomycin, and 1% L-glutamine in
humidiﬁed air containing 5%CO2 at 37C.HSCswere cultured
for more than 14 days to fully transform to MF-HSCs.38
Treatment of MF-HSCs with STS, FAS Ligand, and
Tunicamycin
MF-HSCs were seeded in 6-well tissue culture plates at
a density of 2.0  105 cells per well and incubated in788humidiﬁed air containing 5% CO2 at 37C overnight. Media
was changed to serum-free conditions in DMEM for
24 hours, and MF-HSCs were treated with 1 mmol/L staur-
osporine (STS; EMD Millipore, Billerica, MA) for 0, 2, 4, 6,
8, and 10 hours to induce apoptosis. To determine whether
apoptosis was Fas-receptoredependent, MF-HSCs were
treated with 50 ng/mL Fas ligand (Calbiochem) in the pres-
ence of 20 ng/mL cycloheximide (Calbiochem) for 10 hours.
To induce ER stress, MF-HSCs were treated with tunica-
mycin at concentrations of 0, 0.5, 1, 2, 5, and 10 mmol/L for
24 hours.
Hepatocyte Isolation
Hepatocytes were isolated from WT and Nogo-B KO mice
by collagenase perfusion as previously described39 with
slight modiﬁcations. Brieﬂy, cells were cultured on collagen-
coated cell culture dishes or glass coverslips in Hepatocyte
Maintenance Medium (Clonetics/Lonza, Basel, Switzerland)
supplemented with Hepatocyte Maintenance Medium Sin-
gleQuots (Clonetics/Lonza) and Matrigel (BD Biosciences,
San Jose, CA). An initial coating density was 0.4  106/mL.
On the following day, cells were replaced with medium
without any supplementation and incubated for 24 hours.
Cells then were subjected to experiments for STS treatment.
Western Blot Analysis
After drug treatment, cells were collected in a lysis buffer
containing50mmol/LTris-HCl,0.1mmol/LEGTA,0.1mmol/L
EDTA, 0.1% SDS, 0.1% deoxycholic acid, 1% (vol/vol)
Nonidet P-40, 5 mmol/L sodium ﬂuoride, 1 mmol/L sodium
pyrophosphate, 1 mmol/L activated sodium vanadate, 0.32%
protease inhibitor cocktail (Roche Diagnostics), and 0.027%
Pefabloc (Roche Diagnostics). Lysates were centrifuged at
14,000  g at 4C for 10 minutes. Protein concentration was
determined using a Lowry assay. An equal amount of protein
(10 to 20 mg) from each sample was loaded onto SDS-PAGE
gels and transferred to 0.2-mmnitrocellulosemembranes (Bio-
Rad,Hercules,CA).After blockingwith 5%nonfat drymilk in
0.1% TBST, membranes were probed with rabbit anti-Nogo
serum (1761A, 1:10,000; a kind gift from Dr. William C.
Sessa, Yale University, New Haven, CT), goat anti-Nogo (N-
18, 1:200; Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
mouse antieheat shock protein 90 (1:1000; BD Biosciences),
mouse anti-Bip (1:1000; BD Biosciences), rabbit antiepoly
(ADP-ribose) polymerase (PARP) (1:1000; Cell Signaling),
rabbit anti-cleaved caspase-3 (1:1000; Cell Signaling), rabbit
anti-cleaved caspase-8 (1:1000; Cell Signaling), rabbit antie
B-cell lymphoma-extra large (1:1000; Cell Signaling), mouse
antiecaspase-9 (1:1000; Cell Signaling), or mouse antie
b-actin (1:5000; Sigma-Aldrich). After washing three times
with TBST for 10 minutes, membranes were incubated with
ﬂuorophore-conjugated secondary antibodies (either 680-nm or
800-nm emission). Detection and quantiﬁcation of bands were
performed using the Odyssey Infrared Imaging System (Li-Corajp.amjpathol.org - The American Journal of Pathology
Nogo-B, Hepatic Apoptosis, and FibrosisBiotechnology, Lincoln, NE). Heat shock protein 90 and b-
actin were used for loading controls.TUNEL and Annexin V Staining
MF-HSCs were ﬁxed with 4% paraformaldehyde in PBS for
1 hour at room temperature, followed by washing with PBS
three times for 5 minutes each time. MF-HSCs then were
incubated with a permeabilization buffer containing 0.1%
Triton X-100 in 0.1% sodium citrate on ice for 5 minutes.
TUNEL staining was performed using a commercial kit
(In Situ Cell Death Detection Kit; Roche Diagnostics) by
incubating MF-HSCs for 1 hour at room temperature.
Recombinant DNase I (3 U/mL; Roche Diagnostics) was
incubated for 10 minutes as a positive control before labeling
procedures. The label solution conjugated with ﬂuorescein
alone was used as a negative control. After washing three
times with PBS for 5 minutes each time, MF-HSCs were
mounted with a mounting media containing DAPI (Invi-
trogen). Annexin V staining was performed using Alexa
Fluor 488econjugated Annexin V/Dead Cell Apoptosis Kit
(Life Technologies). Images were taken using a ﬂuorescent
microscope (Eclipse E800; Nikon) and recorded with
Openlab3 software (PerkinElmer).The American Journal of Pathology - ajp.amjpathol.orgNogo-B Knockdown in Human Hepatic Stellate Cell
Line (LX2)
LX-2 cells were a kind gift from Dr. Scott L. Friedman
(Mount Sinai School of Medicine, New York, NY).40 Cells
were seeded on 6-well tissue culture plates at a density of
1.5  105 cells per well and incubated in humidiﬁed air
containing 5% CO2 overnight at 37C. Cells were trans-
fected with 100 nmol/L Nogo-B small-interfering RNA in
750 mL Opti-MEM (Gibco, Invitrogen) with 2 mL Oligo-
fectamine (Invitrogen) and incubated for 6 hours. Then, 750
mL of DMEM containing 20% FBS and 2% L-glutamine
was added to each well. After 48 hours of incubation, these
cells were starved in DMEM without FBS for 24 hours and
treated with 100 nmol/L STS for 0, 2, 4, 6, 8, and 10 hours.Nogo-B Overexpression in LX2
LX2 cells were seeded in 12-well tissue culture plates at
a density of 1.0 105 cells/well and incubated in humidiﬁed air
containing 5% CO2 overnight at 37C. Cells were transfected
with 0.5 mg of hemagglutinin-tagged Nogo-B plasmid
(or pcDNA3 vector alone as a negative control) in 500 mL
Opti-MEM (Gibco, Invitrogen) with 1.5 mL FuGENE 6Figure 1 Lack of Nogo-B decreases liver
ﬁbrosis and increases apoptotic cells in ﬁbrotic
areas in mice. A: Representative images of Sirius
Red staining. Inset corresponds to F. B: Percent-
ages of Sirius Redepositive areas in cirrhotic livers
from WT and Nogo-B KO mice. C: Hydroxyproline
levels in control and cirrhotic livers isolated from
WT and Nogo-B KO mice. D: Collagen 1a1 expres-
sion in control and cirrhotic livers isolated from WT
and Nogo-B KO mice. E: Transforming growth
factor-b1 (TGF-b1) expression in control and
cirrhotic livers isolated from WT and Nogo-B KO
mice (nZ 7 per group). Values represent means 
SE. *P < 0.05, **P < 0.01. F: Immunohisto-
chemistry of cleaved caspase-3 in cirrhotic livers
isolated from WT and Nogo-B KO mice. Red
arrowheads in the enlarged images (lower panel)
indicate cleaved caspase-3epositive cells in the
ﬁbrotic area. Serial liver sections from the same
mice were stained for Sirius Red and cleaved
caspase-3. At least ﬁve images were taken for each
group. G: Co-localization of apoptotic cells with a-
SMA in cirrhotic livers isolated from WT and Nogo-
B KO mice. a-SMA is shown in green, apoptotic
(TUNEL-positive) cells in red, and nuclei stained
with DAPI in blue. Arrows indicate apoptotic cells
positive with a-SMA. Scale bars: 100 mm.
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Figure 2 Lack of Nogo-B facilitates apoptosis
of mouse MF-HSCs in vitro. MF-HSCs were treated
with 1 mmol/L STS for 16 hours to induce apoptosis.
A: TUNEL staining (green, TUNEL-positive nuclei;
blue, DAPI and percentages of TUNEL-positive
nuclei in WT and Nogo-B KO MF-HSCs). Represen-
tative images are shown from three independent
experiments. B: Annexin V staining (green, Annexin
Vepositive nuclei; blue, DAPI and percentages of
Annexin Vepositive nuclei in WT and Nogo-B KO
MF-HSCs). The numbers of TUNEL- and Annexin
Vepositive nuclei (green) were divided by the
total numbers of nuclei determined by DAPI
staining (blue). At least ﬁve images were taken for
each group. Representative images are shown from
three independent experiments. Values represent
means  SE. **P < 0.01. Scale bars: 100 mm.
Tashiro et al(Roche Diagnostics) and incubated for 6 hours. Then, 500 mL
of DMEM containing 10% FBS and 1% L-glutamine was
added to each well. After 48 hours of incubation, cells were
starved in DMEM without FBS for 24 hours, followed by
treatment with 100 nmol/L STS for 4 and 8 hours, respectively.
For immunocytochemistry, cells were washed with cold
PBS and ﬁxed with 4% paraformaldehyde in PBS for
20 minutes at room temperature. After washing three times
with PBS for 5 minutes each time, cells were incubated in
a buffer containing 0.3% Triton X-100, 5% donkey serum,Figure 3 Markers of apoptosis are increased in mouse MF-HSCs that lack Nogo-
Representative Western blot analysis of apoptotic markers, including cleaved PAR
control. B: Quantiﬁcation of Western blot analysis from at least three to ﬁve indep
790and 1% bovine serum albumin in PBS at room temperature
for 1 hour. After washing with PBS, cells were incubated
with antibodies including rat anti-HA (1:1000; Roche
Diagnostics) and rabbit anti-cleaved caspase-3 (1:1000; Cell
Signaling), which were diluted with 1% bovine serum
albumin in PBS overnight at 4C. Cells then were incubated
with Alexa Fluor 488 donkey anti-rat IgG (1:500; Invi-
trogen) or Alexa Fluor 588 donkey anti-rabbit IgG (1:500;
Invitrogen) as a secondary antibody for 1 hour at room
temperature. Cells were mounted with DAPI-containingB. MF-HSCs were treated with 1 mmol/L STS for 0, 2, 4, 6, 8, and 10 hours. A:
P; cleaved caspase-3, -8, and -9; and Bcl-xL. b-actin was used as a loading
endent experiments. Values represent means  SE. *P < 0.05, **P < 0.01.
ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Lack of Nogo-B does not inﬂuence hepatocyte apoptosis in
response to STS. Hepatocytes were isolated from WT and Nogo-B KO mice
and treated with 10 mmol/L STS for 0, 2, 4, 6, 8, and 10 hours. Heat shock
protein 90 (Hsp90) was used as a loading control. Representative images
are shown from two independent experiments.
Nogo-B, Hepatic Apoptosis, and Fibrosismedia (Invitrogen). Images were taken by a ﬂuorescent
microscope (Eclipse E800; Nikon) and recorded using
Openlab3 software (PerkinElmer).Statistical Analysis
Data were expressed as means  SE. Statistical differences
among the mean values of multiple groups were determined
using analysis of variance followed by the Student’s t-test.
P values < 0.05 were considered statistically signiﬁcant.Figure 5 Knockdown of Nogo-B increases apoptosis in human hepatic
stellate cells (LX2). LX2 cells with or without Nogo-B siRNA were treated
with 100 nmol/L STS for 0, 2, 4, 6, 8, and 10 hours. Western blot analysis
for apoptotic markers, including cleaved PARP, cleaved caspase-3 and -9,
and Bcl-xL, was performed. b-actin was used as a loading control. Repre-
sentative images are shown from two independent experiments.Results
Lack of Nogo-B Reduces Fibrosis and Facilitates
Apoptosis in Fibrotic Areas of the Mouse Cirrhotic Liver
Sirius Red staining was performed in cirrhotic livers isolated
from WT and Nogo-B KO mice that underwent CCl4
inhalation for 12 weeks (Figure 1A). Liver ﬁbrosis was
reduced signiﬁcantly in Nogo-B KO livers compared with
WT livers (Figure 1, A and B) (P < 0.05). Consistently,
hydroxyproline levels were signiﬁcantly lower in Nogo-B
KO livers than in WT livers (Figure 1C) (P < 0.05).
Collagen 1a1 expression also was signiﬁcantly lower in
Nogo-B KO livers (Figure 1D) (P < 0.05), whereas trans-
forming growth factor-b1 expression did not differ signiﬁ-
cantly between the two groups (Figure 1E). Apoptotic cells,
as indicated by cleaved caspase-3 immunolabeling, were
seen in ﬁbrotic regions of Nogo-B KO livers, whereas they
were much less apparent in WT livers (Figure 1F). Nogo-B
KO cirrhotic livers showed co-localization of TUNEL
staining with a-SMAepositive cells, whereas TUNEL
staining was not apparent in WT cirrhotic livers (Figure 1G
and Supplemental Figure S1). These results suggest that the
lack of Nogo-B reduces ﬁbrosis and enhances apoptosis of
activated HSCs in experimental cirrhosis.The American Journal of Pathology - ajp.amjpathol.orgLack of Nogo-B Facilitates Apoptosis of MF-HSCs
The role of Nogo-B in apoptosis of MF-HSCs was examined
using STS, an inducer of apoptosis.41e43WT and Nogo-B KO
MF-HSCs were treated with 1 mmol/L STS for 16 hours and
examined for TUNEL and Annexin V labeling. Nogo-B KO
MF-HSCs showed signiﬁcantly higher percentages of
TUNEL- and Annexin Vepositive nuclei compared with WT
MF-HSCs (Figure 2, A and B) (P < 0.01).
We also determined the levels of several apoptotic
markers in WT and Nogo-B KO MF-HSCs after treatment
with 1 mmol/L STS for 0, 2, 4, 6, 8, and 10 hours (Figure 3).
Levels of cleaved PARP were increased in a time-dependent
manner in both WT and Nogo-B KO MF-HSCs, but were
signiﬁcantly higher in Nogo-B KO MF-HSCs 4, 6, and
10 hours after STS treatment (P < 0.05 for 4 and 6 hours
and P < 0.01 for 10 hours) (Figure 3B). Similarly, cleaved
caspase-3 levels were increased signiﬁcantly in Nogo-B KO
MF-HSCs 4, 6, and 8 hours after STS treatment (P < 0.05
for 4 and 6 hours and P < 0.01 for 8 hours) (Figure 3B).
The levels of cleaved caspase-8 also were increased
signiﬁcantly in Nogo-B KO MF-HSCs 4, 6, and 8 hours
after STS treatment (P < 0.05) (Figure 3B). Cleaved
caspase-9 and Bcl-xL levels did not differ between these
two groups at all time points examined (Figure 3B). This
may reﬂect the fact that Bcl-xL primarily acts on mito-
chondria and prevents apoptosis by inhibiting the activity of
caspase-9.44,45 These results indicate that the lack of Nogo-
B facilitates apoptosis of MF-HSCs in response to STS.
Lack of Nogo-B Does Not Inﬂuence Hepatocyte
Apoptosis in Response to STS
To investigate the possibility that Nogo-B may modulate
apoptosis in hepatocytes, hepatocytes from WT and Nogo-B791
Tashiro et alKO mice were treated with STS (Figure 4). Hepatocytes
required a higher dose of STS than MF-HSCs to induce
apoptosis (10 versus 1 mmol/L, respectively). Moreover,
there was no difference in the levels of apoptotic markers
between WT and Nogo-B KO hepatocytes. These results
indicate that the absence of Nogo-B preferentially sensitizes
MF-HSCs rather than hepatocytes to apoptosis under
conditions of experimental cirrhosis.
Knockdown of Nogo-B Increases Apoptosis in Human
HSCs (LX2)
To conﬁrm the role of Nogo-B in apoptosis in human MF-
HSCs, LX2 cells were transfected with Nogo-B small-
interfering RNA to suppress Nogo-B expression. We then
tested apoptosis in those cells treated with 100 nmol/L STS
for 0, 2, 4, 6, 8, and 10 hours (Figure 5). Nogo-B small-
interfering RNA resulted in a 66% reduction of Nogo-B
expression. Similar to the results in mouse MF-HSCs, the
levels of cleaved PARP and caspase-3 were increased in
LX2 cells treated with Nogo-B small-interfering RNA
compared with controls, however, the levels of cleaved
caspase-9 and Bcl-xL did not differ. Consistent with mouse
MF-HSCs, knockdown of Nogo-B resulted in enhanced
apoptosis in human MF-HSCs in response to STS.
Overexpression of Nogo-B Blocks Apoptosis in Human
HSCs (LX2)
To determine the effect ofNogo-B overexpression on apoptosis
of human MF-HSCs, LX2 cells were transfected with HA-
tagged human Nogo-B plasmid and treated with 100 nmol/L
STS for 8 hours. The transfection resulted in a sevenfold higher
level of Nogo-B over the endogenous Nogo-B level found in
nontransfected LX2 cells (data not shown). As shown in
Figure 6, the majority of HAeNogo-Bepositive cells wereFigure 6 Overexpression of Nogo-B blocks apoptosis in human hepatic
stellate cells (LX2). LX2 cells were transfected with HA-tagged human
Nogo-B plasmid to overexpress Nogo-B. Cells were treated with 100 nmol/L
STS for 8 hours. Representative immunoﬂuorescence images of HA and
cleaved caspase-3 in LX2 cells 8 hours after STS treatment (green, HA; red,
cleaved caspase-3; blue, DAPI). Arrows indicate HAeNogo-Bepositive
cells. Scale bars: 20 mm. Cleaved caspase-3epositive cells were counted in
LX2 cells with and without Nogo-B overexpression and divided by the total
number of nuclei. At least eight images were taken per group. Values
represent means  SE. **P < 0.01.
792negative for cleaved caspase-3. In fact, the percentage of
cleaved caspase-3epositive cells was signiﬁcantly lower in
HAeNogo-Bepositive cells than in nontransfected cells (4.2%
versus 29.4%, respectively; P < 0.01). These results suggest
that MF-HSCs become resistant to apoptosis with Nogo-B
overexpression. These data also lend support to our earlier
data that the lack of Nogo-B facilitates apoptosis of MF-HSCs.
Nogo-B Is Involved in ER Stress-Induced Apoptosis in
MF-HSCs
To examine how Nogo-B inﬂuences apoptosis of MF-HSCs,
WT and Nogo-B KO MF-HSCs were treated with tunica-
mycin, an ER stress inducer, and Fas ligand, an inducer of
apoptosis through the death receptor pathway. Tunicamycin
treatment (0, 0.5, 1, 2, 5, and 10 mg/mL for 24 hours)
generated signiﬁcantly higher levels (P < 0.01) of cleaved
caspase-3 and -8 in Nogo-B KO MF-HSCs than in WT MF-
HSCs at virtually all concentrations examined, whereas the
levels of Bip, a marker of the ER stress response, were
similar in WT and Nogo-B KO MF-HSCs (Figure 7A). In
contrast, Fas ligand treatment (50 ng/mL for 10 hours in the
presence of 20 ng/mL cycloheximide) did not affect the
levels of apoptotic markers (cleaved PARP and cleaved
caspase-3 and -8) between WT and Nogo-B KO MF-HSCs
(Figure 7B). In addition, levels of Bcl-xL, which is related
to the mitochondrial pathway of apoptosis, were not
different between WT and Nogo-B KO MF-HSCs in
response to STS (Figure 3B). These results suggest that
the higher degree of apoptosis observed in Nogo-B KO
MF-HSCs is attributable in part to ER stress-induced
apoptosis (Figure 7C).Discussion
Experimental studies have shown that inducing HSC
apoptosis may reduce hepatic ﬁbrosis.46e50 In this study, we
discovered that lack of Nogo-B reduces liver ﬁbrosis and
enhances apoptosis of myoﬁbroblasts derived from HSCs
(MF-HSCs, ie, activated HSCs) in mice that underwent CCl4
inhalation for 12 weeks. Enhanced apoptosis resulting from
the absence of Nogo-B was recapitulated in vitro as well.
Cultured myoﬁbroblasts derived from HSCs of Nogo-B KO
mice, as well as human hepatic stellate cells (LX2) with
Nogo-B gene knockdown, showed a greater degree of
apoptosis than their respective controls in response to an
apoptotic stimulus. Furthermore, Nogo-B overexpression
decreased the susceptibility of LX2 cells to apoptosis. These
ﬁndings suggest that Nogo-B has an anti-apoptotic effect on
MF-HSCs and that the enhanced apoptosis of MF-HSCs
lacking Nogo-B may be responsible for the reduced
ﬁbrosis observed in the livers of Nogo-B KO mice.
We previously reported that Nogo-B levels are increased
in ﬁbrotic areas of human cirrhotic liver specimens as well
as in mouse cholestatic models of ﬁbrosis after bile ductajp.amjpathol.org - The American Journal of Pathology
Nogo-B, Hepatic Apoptosis, and Fibrosisligation. Nogo-B gene deletion blocks the progression of
cirrhosis and portal hypertension, suggesting that Nogo-B
promotes liver ﬁbrosis. This proﬁbrotic effect of Nogo-B
was mediated through transforming growth factor-b/Smad2
signaling in myoﬁbroblasts.30 This study conﬁrms that
Nogo-B facilitates ﬁbrosis in the CCl4 model of cirrhosis and
supports our earlier studies that showed a proﬁbrotic role
for Nogo-B in the liver. Previous work using Nogo-B KO
mice in a kidney injury model observed no signiﬁcant
differences in tissue ﬁbrosis.29 The length of injury and the
different organ systems studied may account for these dif-
ferent outcomes.
We also examined pathways through which Nogo-B
performs anti-apoptosis of MF-HSCs with a focus on ER
stress, Fas ligand, and mitochondrial pathways. Because ER
stress induces apoptosis in HSCs12 and Nogo-B regulates
ER structure,17,18,28,51 we hypothesized that the anti-
apoptotic effect of Nogo-B on MF-HSCs might be medi-
ated by ER stress. In fact, treatment with tunicamycin
signiﬁcantly increased the levels of cleaved caspase-3 and -8
in Nogo-B KO MF-HSCs compared with their WTFigure 7 Lack of Nogo-B increases ER stress-induced apoptosis inmouseMF-HSC
24 hours. A representativeWestern blot analysis from at least three to ﬁve independe
Bip was used as an ER stress marker and b-actin was used as loading control. Values r
ligand (FasL) for 10 hours in the presence of 20 ng/mL cycloheximide (CHX), and blot
as loading control. C: A diagram of apoptotic pathways that includes a putative role
receptore, mitochondria-, and ER stressemediated pathways. Nogo-B reduces MF-
molecule.
The American Journal of Pathology - ajp.amjpathol.orgcounterparts. These facts indicate that the anti-apoptotic role
of Nogo-B in MF-HSCs is caused, at least in part, by its
involvement in ER stress (Figure 7C). Thus, lack of Nogo-B
appears to increase the susceptibility of MF-HSCs to ER
stress, thereby predisposing them to apoptosis.
In contrast, our study indicated that the anti-apoptotic role of
Nogo-B in MF-HSCs is not likely via the mitochondrial
pathway because the level of Bcl-xL, an indicator of
mitochondria-mediated apoptosis, did not differ between WT
and Nogo-B KOMF-HSCs in response to STS. Although we
found signiﬁcantly higher levels of cleaved caspase-8 inNogo-
B KOMF-HSCs in response to STS, caspase-8 is known to be
activated through the ER stress pathway52 and/or the death-
receptor pathway.53e55 In addition, treatment with Fas
ligand, a pro-apoptotic death ligand, did not generate any
difference in the level of cleaved caspase-8 between these two
groups of MF-HSCs, ruling out a role for Fas-mediated cell
death.
The regulation of HSC apoptosis by Nogo-B appears to
involve complex processes. First, ER stress-induced
apoptosis takes place through many known and unknowns.A: MF-HSCswere treatedwith tunicamycin (0, 0.5, 1, 2, 5, and 10mg/mL) for
nt experiments and quantiﬁcation of cleaved caspase-3 and -8 levels is shown.
epresent means SE. **P< 0.01. B: MF-HSCs were treated with 50 ng/mL Fas
ted for cleaved PARP, cleaved caspase-3 and -8, and Nogo-B. b-actin was used
of Nogo-B. At least three major apoptotic pathways exist, including the death
HSC apoptosis by protecting cells from ER stress. Bcl-xL is an anti-apoptotic
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Tashiro et alpathways involving various ligands, receptors, proteases,
and so forth. Second, although Nogo-B resides in the ER
and is known to regulate ER structure, the functional roles
and mechanisms of Nogo-B in the ER are largely unknown.
The current literature examining the role of Nogo-B in ER
stress-induced apoptosis is extremely complicated. Nogo-B
blocks ER stress-induced apoptosis of smooth muscle cells
in the pulmonary artery, but not in smooth muscle cells of
the carotid artery.28
The involvement of Nogo-B in apoptosis also has been
reported in cancer cells. However, those reports also are
conﬂicting. One study showed increased apoptosis in
HeLa-derived D98/AH2 cells transiently transfected with
Nogo-B.56 Another study also presented the pro-apoptotic
effect of Nogo-B on CGL4 (a HeLa-derived cell line),
SaOS-2 (an osteosarcoma cell line), MeWo (a melanoma cell
line), HT-1080 (a ﬁbrosarcoma cell line), and HFL (the
immortalized, nonmalignant, human ﬁbroblast cell line), by
transiently transfecting them with Nogo-B.57 In contrast,
Oertle et al58 documented that SaOS-2 stably transfected with
Nogo-B does not differ in apoptotic effects from its control.
These discrepancies may suggest that timing and length of
Nogo-B overexpression are a key to induce apoptosis in
certain cancer cells and that those cancer cells with stable
overexpression of Nogo-B might develop an adaptive ma-
chinery that protects them from apoptosis. Overall, Nogo-B
may function as a pro-apoptotic or anti-apoptotic protein,
depending on the speciﬁc cell type. Further studies are needed
to determine detailed mechanisms by which Nogo-B regu-
lates apoptosis.
Apoptosis also can mediate proﬁbrotic responses in the
liver depending on the cell type involved. Hepatocyte
apoptosis is thought to facilitate ﬁbrosis by triggering and
maintaining HSC activation in response to hepatic insults.59
To address this issue, we examined whether the levels of
apoptotic markers (cleaved PARP, cleaved caspase-3 and-8,
and Bcl-xL) in cultured WT and Nogo-B KO hepatocytes
differed in response to STS. No differences in apoptotic
activity were observed, indicating that the anti-apoptotic
effect of Nogo-B is speciﬁc to MF-HSCs.
In conclusion, absence of Nogo-B speciﬁcally increases
apoptotic responses of MF-HSCs, which is associated
with a reduction in hepatic ﬁbrosis. Therefore, Nogo-B
may be a potential target for the treatment of liver ﬁbrosis/
cirrhosis.
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